Last reviewed · How we verify
Placebo, docetaxel
Docetaxel is a microtubule-stabilizing agent that prevents microtubule disassembly, leading to cell cycle arrest and apoptosis in cancer cells.
Docetaxel is a microtubule-stabilizing agent that prevents microtubule disassembly, leading to cell cycle arrest and apoptosis in cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer.
At a glance
| Generic name | Placebo, docetaxel |
|---|---|
| Sponsor | Akeso |
| Drug class | Taxane; microtubule stabilizer |
| Target | Beta-tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel binds to beta-tubulin and stabilizes microtubules, preventing their depolymerization during cell division. This disruption of the mitotic spindle causes cells to arrest in the G2/M phase of the cell cycle and undergo apoptosis. It is a semi-synthetic taxane derived from the Pacific yew tree.
Approved indications
- Metastatic breast cancer
- Non-small cell lung cancer
- Prostate cancer
- Gastric cancer
- Head and neck cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Alopecia
- Nausea/vomiting
- Diarrhea
- Fatigue
- Hypersensitivity reactions
Key clinical trials
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
- Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (PHASE3)
- Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (PHASE2)
- Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (PHASE2)
- Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) (PHASE3)
- Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo, docetaxel CI brief — competitive landscape report
- Placebo, docetaxel updates RSS · CI watch RSS
- Akeso portfolio CI